title: Are patients with cancer receiving adequate treatment for thrombosis? Results from FRONTLINE.
abstract: The current practice of clinicians worldwide in the treatment of venous thromboembolism was assessed via responses to the FRONTLINE survey. Significant regional differences in practice were noted. Use of low-molecular-weight heparin was reported as the most common initial treatment for venous thromboembolism, although, in North America, unfractionated heparin was widely used to treat surgical cancer patients after a thrombotic episode. Oral anticoagulants were favoured for long-term treatment of venous thromboembolism, particularly in Western Europe and North America. Case study reports from the survey revealed that a substantial proportion of patients with cancer had been perceived to be at low risk of thrombosis, had consequently not received thromboprophylaxis and developed VTE.
authors.affiliation: Department of Haematology-Oncology, National University Hospital, 5 Lower Kent Ridge Road, Singapore. johnwong@nus.edu.sg <johnwong@nus.edu.sg>
authors.forename: John E-L
authors.initials: JE
authors.lastname: Wong
mesh_terms: D001291:Attitude of Health Personnel; D005060:Europe; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D019538:Health Care Surveys; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D009656:North America; D010820:Physicians; D020246:Venous Thrombosis / Q000209:etiology* / Q000517:prevention & control*
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight